Combination strategies for lupus nephritis: facts and controversies

References

• Mok CC, Kwok RCL, Yip PSF. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–2160.
   PubMed Web of Science ®Google Scholar
• Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12:221–234.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68:1432–1441. DOI:10.1002/art.39594.
   PubMed Web of Science ®Google Scholar
• Kharawala S, Kaur G, Shukla H, et al. Health-related quality of life, fatigue and health utilities in lupus nephritis: a systematic literature review. Lupus. 2022;31:1029–1044.
   PubMed Web of Science ®Google Scholar
• Jolly M, Toloza S, Goker B, et al. Disease-specific quality of life in patients with lupus nephritis. Lupus. 2018;27:257–264.
   PubMed Web of Science ®Google Scholar
• Wang S, Panush RS. Certain perspectives about the use of corticosteroids for managing hospitalized patients with rheumatic diseases. Clin Rheumatol. 2020;39:3131–3136.
   PubMed Web of Science ®Google Scholar
• Albert DA, Hadler NM, Ropes MW. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum. 1979;22:945–953.
   PubMedGoogle Scholar
• Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614–619. .
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549–557.
   PubMed Web of Science ®Google Scholar
• Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248–257.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741–745.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–2228.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–1112.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–2131.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61–64.
   PubMed Web of Science ®Google Scholar
• Tamirou F, Husson SN, Gruson D, et al. Brief report: the euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-müllerian hormone. Arthritis Rheumatol. 2017;69:1267–1271.
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156–1162.
   PubMed Web of Science ®Google Scholar
• Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005;10:504–510.
   PubMed Web of Science ®Google Scholar
• Thong KM, Chan TM. Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis. Lupus. 2019;28:334–346.
   PubMed Web of Science ®Google Scholar
• Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:429–438. . 10.1016/j.berh.2017.09.010
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75:30–36.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, Ying SKY, et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 2020;79:1070–1076.
   PubMed Web of Science ®Google Scholar
• Austin HA, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901–911.
   PubMed Web of Science ®Google Scholar
• Zavada J, Pesickova S, Rysava R, et al. Cyclosporine a or intravenous cyclophosphamide for lupus nephritis: the cyclofa-lune study. Lupus. 2010;19:1281–1289.
   PubMed Web of Science ®Google Scholar
• Závada J, Sinikka Pesicková S, Rysavá R, et al. Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine a. Lupus. 2014;23:69–74.
   PubMed Web of Science ®Google Scholar
• Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27:1467–1472.
   PubMed Web of Science ®Google Scholar
• Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57:235–244.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zhang H, Peng X, et al. Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: a randomized clinical trial. JAMA Netw Open. 2022;5:e224492.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797–808. .
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100:753–779. .
   PubMed Web of Science ®Google Scholar
• Mok CC, Hamijoyo L, Kasitanon N, et al. the Asia-pacific league of associations for rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatol. 2021;3:e517–531. .
   Google Scholar
• Fanouriakis A, Kostopoulou M, Cheema K, et al. Update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2019;79:713–723. .
   Web of Science ®Google Scholar
• Tanaka Y, O’neill S, Li M, et al. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific Region. Arthritis Care Res (Hoboken). 2022;74:187–198.
   PubMed Web of Science ®Google Scholar
• Kho M, Cransberg K, Weimar W, et al. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother. 2011;12:1217–1231.
   PubMed Web of Science ®Google Scholar
• Bao H, Liu Z-H, Xie H-L, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001–2010.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162:18–26.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu Z, Zhou M, et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. 2017;28:3671–3678.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Lerma E, Engelke K, et al. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev Clin Pharmacol. 2022;15:515–529.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Solomons N, Pendergraft WF, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95:219–231.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070–2080. .
   PubMed Web of Science ®Google Scholar
• Arriens C, Teng YKO, Ginzler EM, et al. Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis. Arthritis Care Res (Hoboken). 2022 Aug 30. DOI:10.1002/acr.25007.
   PubMed Web of Science ®Google Scholar
• Saxena A, Teng YKO, Collins C, et al. EULAR abstract archive [internet]. Voclosporin for lupus nephritis: results of the two-year AURORA 2 continuation sutdy. Ann Rheum Dis. 2022;81(suppl 1):325.
   Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215–1226.
   PubMed Web of Science ®Google Scholar
• Rydén-Aulin M, Boumpas D, Bultink I, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3:e000163.
   PubMedGoogle Scholar
• Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol. 2015;33:449–456.
   PubMed Web of Science ®Google Scholar
• Díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11:357–364.
   PubMed Web of Science ®Google Scholar
• Weidenbusch M, Römmele C, Schröttle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28:106–111.
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368–2379.
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402.
   PubMed Web of Science ®Google Scholar
• Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017;56:1227–1237.
   PubMed Web of Science ®Google Scholar
• Reddy VR, Pepper RJ, Shah K, et al. Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? Rheumatology (Oxford). 2022;61:2894–2904.
   PubMed Web of Science ®Google Scholar
• Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:100–107. .
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–263.
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62:201–210.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bae S-C, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355–363.
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69:1016–1027.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79:1340–1348.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven Rf, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–1349.
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117–1128. .
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol. 2022;17:1620–1630.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101:403–413.
   PubMed Web of Science ®Google Scholar
• Morand EF, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020;59:2930–2938.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14:R33.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77:883–889.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:323–331.
   PubMed Web of Science ®Google Scholar
• Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:332–340.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Anifrolumab: first approval. Drugs. 2021;81:1795–1802.
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211–221.
   PubMed Web of Science ®Google Scholar
• Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208–219.
   PubMedGoogle Scholar
• Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase iii extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 2023;75:253–265.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81:496–506.
   PubMed Web of Science ®Google Scholar
• Dörner T, Posch MG, Li Y, et al. Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78:641–647.
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399:161–171.
   PubMed Web of Science ®Google Scholar
• Furie R, Parikh S, Maiquez A, et al. Treatment of SLE with the immunoproteasome inhibitor KZR-616: results from the first four cohorts of the MISSION study, an open-label phase 1b dose escalation trial. Ann Rheum Dis. 2020;79(Suppl 1):1482.
   Google Scholar
• Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65:2672–2679.
   PubMed Web of Science ®Google Scholar
• Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2021;36:1474–1483.
   PubMed Web of Science ®Google Scholar
• Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73:121–131.
   PubMed Web of Science ®Google Scholar
• Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial. Ann Intern Med. 2021;174:1647–1657.
   PubMed Web of Science ®Google Scholar
• Teng YKO, van Maurik A, Clark KL, et al. Pharmacodynamic effect of sequential belimumab and rituximab therapy in patients with systemic lupus erythematosus: the phase 3, randomized, placebo-controlled BLISS-BELIEVE study. DOI:10.1136/annrheumdis-2022-eular.2433 Available from.
   Google Scholar
• van Schaik M, Arends EJ, Soonawala D, et al. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials. 2022;23:939.
   PubMedGoogle Scholar
• Jesus D, Rodrigues M, da Silva J a P, et al. Multitarget therapy of mycophenolate mofetil and cyclosporine a for induction treatment of refractory lupus nephritis. Lupus. 2018;27:1358–1362.
   PubMed Web of Science ®Google Scholar
• Cc M. Pro: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant. 2016;31:1561–1566.
   PubMedGoogle Scholar
• Ogawa H, Kameda H, Amano K, et al. Efficacy and safety of cyclosporine a in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19:162–169.
   PubMed Web of Science ®Google Scholar
• Almutairi A, Alkathiri Z, Al-Mayouf SM. Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis. Int J Pediatr Adolesc Med. 2018;5:99–102.
   PubMedGoogle Scholar
• Choi C-B, Won S, Bae S-C. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27:1007–1011.
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Torres-Salido MT, Medrano AS, et al. Long-term outcomes–mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010;25:3939–3948.
   PubMed Web of Science ®Google Scholar
• Lanata CM, Mahmood T, Fine DM, et al. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus. 2010;19:935–940.
   PubMed Web of Science ®Google Scholar
• Mok CC, To CH, Yu KL, et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22:1135–1141.
   PubMed Web of Science ®Google Scholar
• Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis. 2015;18:154–163.
   PubMed Web of Science ®Google Scholar
• Bell CF, Chung J, Rubin B. Real-world clinical outcomes in belimumab-treated US African American and Hispanic patients with systemic lupus erythematosus: a retrospective, observational study. Rheumatol Ther. 2023 Jan 18. DOI:10.1007/s40744-022-00524-y.
   Web of Science ®Google Scholar
• Escalera CR, Guisado ÁMZ, Mateo FJ, et al. Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients. Clin Rheumatol. 2022;41:3373–3382.
   PubMed Web of Science ®Google Scholar
• Babini A, Cappuccio AM, Caprarulo C, et al. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: results from a 24-month OBSErve study in Argentina. Lupus. 2020;29:1385–1396.
   PubMed Web of Science ®Google Scholar
• Sebastiani GD, Spinelli FR, Bartoloni E, et al. Baseline characteristics of systemic lupus erythematosus patients included in the lupus Italian registry of the Italian society for rheumatology. Lupus. 2021;30:1233–1243.
   PubMed Web of Science ®Google Scholar
• Trentin F, Gatto M, Zen M, et al. Effectiveness, tolerability, and safety of belimumab in patients with refractory sle: a review of observational clinical-practice-based studies. Clin Rev Allergy Immunol. 2018;54:331–343.
   PubMed Web of Science ®Google Scholar
• Gatto M, Saccon F, Andreoli L, et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRliSS-LN). Results from a large, nationwide, multicentric cohort. J Autoimmun. 2021;124:102729.
   PubMed Web of Science ®Google Scholar
• Mejia-Vilet JM, Malvar A, Arazi A, et al. The lupus nephritis management renaissance. Kidney Int. 2022;101:242–255.
   PubMed Web of Science ®Google Scholar
• Landewé RBM, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347–356.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Aranow C, Asukai Y, et al. Impact of belimumab on organ damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2022;74:1822–1828.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Fukusumi Y, Ivanov V, et al. Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton. Faseb J. 2021;35:e21983.
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Windpessl M, Pieringer H, et al. Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev. 2017;16:633–643.
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Vital EM, McElvenny DM, et al. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2019;71:1812–1823.
   PubMed Web of Science ®Google Scholar
• Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80:1255–1265.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39–52.
   PubMed Web of Science ®Google Scholar
• Chatham W, Chadha A, Fettiplace J, et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017;26:1483–1490.
   PubMed Web of Science ®Google Scholar
• Nagel J, Saxne T, Geborek P, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017;26:1072–1081.
   PubMed Web of Science ®Google Scholar
• Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012;39:1632–1640.
   PubMed Web of Science ®Google Scholar
• Schiavoni I, Olivetta E, Natalucci F, et al. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab. Lupus. 2023;32:394–400.
   PubMed Web of Science ®Google Scholar
• Prendecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis. 2021;80:1322–1329.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Tixagevimab + cilgavimab: first approval. Drugs. 2022;82:1001–1010.
   PubMed Web of Science ®Google Scholar
• Kitada A, Nakai T, Fukui S, et al. Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: a retrospective single-center analysis in Japan. Lupus. 2023;32:352–362.
   PubMed Web of Science ®Google Scholar
• Webster P, Wardle A, Bramham K, et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 2014;23:1192–1196.
   PubMed Web of Science ®Google Scholar
• Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
   PubMed Web of Science ®Google Scholar
• Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Women’s Health. 2022;14:199–211.
   PubMed Web of Science ®Google Scholar
• Gerosa M, Argolini LM, Artusi C, et al. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol. 2018;11:987–998.
   PubMed Web of Science ®Google Scholar